stockrowInovio Pharmaceuticals, Inc.
INOInovio Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $65,300.00, down 70.0% from fiscal 2024.
- Revenue
- −83.2%
- EPS
- +88.5%
- Free cash flow
- +13.4%
Quarter to June 2026, against a year earlier
Follow INO
Alert me
Inovio Pharmaceuticals, Inc. (INO) EV/Sales
As of 6 November 2026, Inovio Pharmaceuticals, Inc. (INO) trades at a EV/Sales of 206×. Over the past ten years it has ranged from −66.8× (November 2023) to 1,439× (June 2020); the current reading is higher than 87% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 103× | — |
| FY2024 | −39.2× | — |
| FY2023 | 25.8× | 109.34% |
| FY2022 | 12.3× | (96.67%) |
| FY2021 | 369× | 179.59% |
| FY2020 | 132× | 73.53% |
| FY2019 | 76.1× | 703.79% |
| FY2018 | 9.5× | 56.77% |
| FY2017 | 6.0× | (48.21%) |
| FY2016 | 11.7× | 60.40% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2025 | 29.0× | — |
| Dec 2024 | −39.2× | — |
| Jun 2024 | 172× | 566.02% |
| Dec 2023 | 25.8× | — |
| 35 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| MGNX MacroGenics, Inc. compare | −0.1× |
| NGEN NervGen Pharma Corp. compare | n/m |
| ANTX AN2 Therapeutics, Inc. compare | n/m |
| SION Sionna Therapeutics, Inc. compare | n/m |
| CNTN Canton Strategic Holdings, Inc. compare | n/m |
| STRO Sutro Biopharma, Inc. compare | 0.1× |
| IPHA Innate Pharma S.A. Sponsored ADR compare | 0.1× |
| ALXO ALX Oncology Holdings Inc. compare | 14.0× |
| INO Inovio Pharmaceuticals, Inc. | 206× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)